Budget impact of Inaxaplin
1 evidence topic · 7 sources
Summary: price, economic evaluations, and forecasts
Inaxaplin has no announced price, and no published cost-effectiveness analysis, budget impact model, health technology assessment, or ICER review of inaxaplin or of any other APOL1-targeted therapy was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Vertex estimates that AMKD affects approximately 150,000 people in the U.S. and Europe, and Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000 people to the target population. Use of inaxaplin would require APOL1 genotyping; Vertex sponsors APOL1 genetic testing at no cost to eligible patients through Labcorp, Natera, and Arkana Laboratories, and no public list price or Medicare payment rate for APOL1 genotyping was identified.